MP46-12 FOURTEEN YEARS OF EXPERIENCE IN LOW DOSE RATE BRACHYTHERAPY FOR EARLY-STAGE PROSTATE CANCER IN ITALY: CHARACTERISTICS AND BIOCHEMICAL OUTCOMES IN A COHORT OF 2279 PATIENTS FROM NINE ITALIAN CENTRES

Abstract

You have accessJournal of UrologyProstate Cancer: Localized IV1 Apr 2014MP46-12 FOURTEEN YEARS OF EXPERIENCE IN LOW DOSE RATE BRACHYTHERAPY FOR EARLY-STAGE PROSTATE CANCER IN ITALY: CHARACTERISTICS AND BIOCHEMICAL OUTCOMES IN A COHORT OF 2279 PATIENTS FROM NINE ITALIAN CENTRES Francesco Mistretta, Andrea Losa, Luciano Dante Nava, Paola Mangili, Giovanni Fellin, Francesco Pio Mangiacotti, Giovanni Ghiso, Vincesco Fusco, Marcello Mignogna, Beniamino La Face, Marco Stefanacci, Giovanni Silvano, and Maria Alessandra Mirri Francesco MistrettaFrancesco Mistretta More articles by this author , Andrea LosaAndrea Losa More articles by this author , Luciano Dante NavaLuciano Dante Nava More articles by this author , Paola MangiliPaola Mangili More articles by this author , Giovanni FellinGiovanni Fellin More articles by this author , Francesco Pio MangiacottiFrancesco Pio Mangiacotti More articles by this author , Giovanni GhisoGiovanni Ghiso More articles by this author , Vincesco FuscoVincesco Fusco More articles by this author , Marcello MignognaMarcello Mignogna More articles by this author , Beniamino La FaceBeniamino La Face More articles by this author , Marco StefanacciMarco Stefanacci More articles by this author , Giovanni SilvanoGiovanni Silvano More articles by this author , and Maria Alessandra MirriMaria Alessandra Mirri More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1445AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives To report the characteristics and biochemical outcomes of a cohort of 2279 localized prostate cancer (PCA) patients treated with low-dose rate brachytherapy ( LDR-BT) in 9 Italian centres (Trento, Milan S. Raffaele, Savona, Brescia, Lucca, Pistoia, Rionero in Vulture, Rome, Taranto). Methods From 1998 to 2012, 2279 patients with localized PCA were treated with iodine-125 (125I) or palladium-103 (103Pd) implants. Global data were collected and retrospectively analyzed. Patients were stratified into low (LR), intermediate (IR) and high (HR) risk groups through the D’Amico’s risk group classification. Freedom from biochemical failure (FFbF) and overall (OS) and disease specific (DSS) survival were calculated according to the Kaplan-Meier method. Biochemical failure was defined according to the Phoenix (PSA nadir plus 2 ng/mL) definition. Results Overall median follow-up was 44 months (3-143). Patients lost to follow up were 243/2279 (10,7%). Median age was 67 years (45-83), median pre-treatment PSA value was 6,66 ng/ml (0,64 -80) and the average pre-implant prostate volume was 35,7 cm3 (4-86,6). According to D’Amico’s risk group classification, 1603 (70,3%) patients has been defined as LR, 493 (21,6%) as IR, 59 ( 2,6%) as HR while 124 (5,4%) were not assessable because of the lack of completeness of data. Neo-adjuvant hormone therapy (OT) was prescribed to the 35,1 % (562/1603) of LR patients, to the 46,6% (230/493) of IR patients and to the 47,5% (28/59) of HR patients. 2197 (96,4%) patients received LDR-BT as a single curative modality and 82 (3,6%) as a boost with external beam RT. I125 and Pd 103 seeds were implanted in 2214 (97,1%) and 65 (2,8%) patients, respectively. The median D90 in patients implanted as monotherapy, was 150,8 Gy for I125 and 126,5 Gy for Pd103. The average V100 was 92% and median 94% for the group of I125 implants, and 88,7% and 90,3 for Pd 103 implants. The 5ys and10ys actuarial OS was 94% and 85%, and the same figures were 99% and 96% for DSS. The 3ys, 5ys,7ys and 10ys FFbF was overall 95%, 93%, 90% and 84%. The 5ys FFbF was 96%, 87% and 75% for LR, IR and HR group respectively. The 5ys FFbF was 95% and 90% if was achieved a D90 > or < 90% of prescribed dose. Conclusions This multi-institutional early report provides information on a large proportion of Italian patients. Our results indicate that a good biochemical outcome is achieved with permanent implant and that an implant of good quality, both for case selection and post implant dosimetric parameters, has been obtained. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e514 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Francesco Mistretta More articles by this author Andrea Losa More articles by this author Luciano Dante Nava More articles by this author Paola Mangili More articles by this author Giovanni Fellin More articles by this author Francesco Pio Mangiacotti More articles by this author Giovanni Ghiso More articles by this author Vincesco Fusco More articles by this author Marcello Mignogna More articles by this author Beniamino La Face More articles by this author Marco Stefanacci More articles by this author Giovanni Silvano More articles by this author Maria Alessandra Mirri More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...